MB2033, an Anti-PD-L1 × IL-2 Variant Fusion Protein, Demonstrates Robust Anti-Tumor Efficacy with Minimal Peripheral Toxicity

MB2033 exhibited significantly reduced regulatory T cell activation, while inducing comparable CD8+ T cell activation to recombinant human IL-2.